2025-10-03 - Analysis Report
Okay, here's the report on UnitedHealth Group Inc. (UNH), incorporating all the data you provided.

**Report on UnitedHealth Group Inc. (UNH)**

**0. Executive Summary**

UNH is underperforming the S&P 500 significantly.  Recent news highlights both growth initiatives and challenges (cyberattack, Medicare Advantage scaling back). Technical indicators are mixed, and analyst opinions lean toward a 'Buy' recommendation, despite the current negative price movement. Accumulative investment is recommended.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** UNH
*   **Company:** UnitedHealth Group Inc. - A diversified healthcare company providing a wide range of healthcare products and services.
*   **UNH Cumulative Return:** -19.29%
*   **VOO (S&P 500) Cumulative Return:** 97.56%
*   **Absolute Divergence:** -116.86% (UNH is lagging the S&P 500 significantly)
*   **Relative Divergence:** 8.3 (This indicates that UNH's divergence from the S&P 500 is near its historical low)

**Analysis:** UNH has significantly underperformed the S&P 500. The large negative divergence suggests substantial relative weakness in UNH's performance compared to the broader market. The Relative Divergence indicates that its current underperformance is close to its historical worst.

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2015-2017  | 58.0%  | 66.4% | 30.0%  | 0.1   | 199.7  |
| 2016-2018  | 41.0%  | 70.4% | 26.0%  | 0.1   | 225.7  |
| 2017-2019  | 36.0%  | 73.8% | 14.0%  | 0.2   | 266.3  |
| 2018-2020  | -43.0% | 81.2% | -67.0% | 0.5   | 317.7  |
| 2019-2021  | 16.0%  | 81.2% | -30.0% | 1.5   | 454.9  |
| 2020-2022  | -1.0%  | 81.2% | 0.0%   | 1.5   | 480.3  |
| 2021-2023  | 24.0%  | 80.8% | 23.0%  | 0.4   | 476.9  |
| 2022-2024  | -27.0% | 78.8% | -47.0% | 0.3   | 458.2  |
| 2023-2025  | -62.0% | 78.8% | -124.0%| 1.3   | 313.5  |

**Analysis:**

*   **CAGR:**  The Compound Annual Growth Rate varies significantly over different periods, with some periods showing strong growth (e.g., 2015-2017) and others showing substantial declines (e.g., 2018-2020, 2023-2025).
*   **MDD:**  The Maximum Drawdown is consistently high, indicating significant potential for losses during downturns.
*   **Alpha:**  Alpha is largely negative in recent years, especially 2018-2020 and 2023-2025 indicating underperformance relative to its benchmark.
*   **Beta:**  Beta varies, with some periods showing low beta (less sensitive to market movements) and others showing higher beta (more sensitive). The 2019-2022 period shows a Beta of 1.5, indicating higher volatility than the market.
*   **Cap(B):** Market capitalization has fluctuated, declining in the latest period after previous growth.

**2. Recent Price Action**

*   **Current Price:** 346.115
*   **Last Market Data:**  Price: 353.72, Previous Close: 348.3, Change: 1.56 (Positive change)
*   **5-day Moving Average:** 347.443
*   **20-day Moving Average:** 336.9638
*   **60-day Moving Average:** 301.1321

**Analysis:** The price is above the 5-day and 20-day moving averages, but below the last-market price, indicating a potentially upward trend in the short term. All average are above the 60-day moving average, suggesting it could be a long-term up trend. The positive change in the last market session is a bullish signal.

**3. Technical Indicators & Outlook**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 48.42 (Neutral - neither overbought nor oversold)
*   **PPO:** -0.4568 (Negative, suggesting a potential downtrend, but close to zero)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe)
*   **Delta_Previous_Relative_Divergence:** 1.2 (+): Short-term increase in relative performance
*   **Expected Return (%):** -147.3 (Significantly negative, indicating potential underperformance compared to the S&P 500 over the long term)

**Analysis:**

*   The MRI indicates a high investment recommendation, but this is contrasted by the negative expected return. This discrepancy requires further investigation.
*   The RSI is neutral.
*   The PPO is slightly negative.
*   The positive change in 'price' and a positive Delta_Previous_Relative_Divergence suggests some short-term upward momentum.
*   A very negative Expected Return suggests the data model forecasts long-term underperformance vs. S\&P500.

**4. Recent News & Significant Events**

*   **Pennant Completes Purchase:** UnitedHealth Group sold operations in Tennessee, Georgia, and Alabama.  This signals a potential shift in business focus or streamlining of operations.
*   **Cyberattack Impact:** The cyberattack is impacting the company's true market value. This is a significant concern.
*   **Health Insurance Market Share:** UnitedHealth is a leader in global growth, but...
*   **Medicare Advantage Scaling Back:** Major health insurers are scaling back Medicare Advantage offerings in 2026.  This could impact UnitedHealth's revenue streams.
*   **CAQH Board Elects New Officers:** Less directly relevant, but provides insight into the broader industry.

**Analysis:** The news is a mixed bag. The sale of assets could be positive or negative depending on the strategic rationale. The cyberattack is a clear negative. The Medicare Advantage changes are a major development to monitor closely.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.96)
*   **Opinions:** 24
*   **Target Price:** Avg: 340.50 / High: 626.00 / Low: 198.00
*   **Recent Rating Changes:** No recent changes indicated.

**Analysis:** Despite the recent underperformance, analysts generally have a positive outlook on UNH. However, the wide range in target prices reflects uncertainty.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-08-11 | 3.76 | 111.62 B$  |
| 2025-05-07 | 6.9  | 109.58 B$  |
| 2024-11-04 | 6.56 | 100.82 B$  |
| 2024-08-09 | 4.58 | 98.86 B$  |
| 2025-08-11 | 4.58 | 98.86 B$  |

**Analysis:** Revenue has been generally increasing. The mixed trend in EPS suggests some volatility in profitability.

**6. Financial Information**

**Revenue and Profitability**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-06-30 | $111.62B   | 17.93%        |
| 2025-03-31 | $109.58B   | 21.70%        |
| 2024-12-31 | $100.81B   | 21.14%        |
| 2024-09-30 | $100.82B   | 22.84%        |
| 2024-06-30 | $98.86B    | 22.31%        |

**Capital and Profitability**

| Quarter    | Equity     | ROE    |
|------------|------------|--------|
| 2025-06-30 | $94.72B   | 3.60%  |
| 2025-03-31 | $95.04B   | 6.62%  |
| 2024-12-31 | $92.66B   | 5.98%  |
| 2024-09-30 | $94.53B   | 6.41%  |
| 2024-06-30 | $89.36B   | 4.72%  |

**Analysis:** Revenue is increasing, however the profit margin has been declining. Equity is stable, with ROE showing some fluctuation.

**7. Comprehensive Analysis**

UNH's recent performance has been weak compared to the S&P 500.  Recent news highlights both growth initiatives and significant challenges. Technical indicators are mixed, and analyst opinions lean toward a 'Buy' recommendation.

**Key Considerations:**

*   **Underperformance:** The significant underperformance compared to the S&P 500 raises concerns.
*   **Cyberattack:** The cyberattack is a major risk factor.
*   **Medicare Advantage:** Changes in the Medicare Advantage market could significantly impact revenue.
*   **Analyst Optimism:**  Analyst ratings remain positive, but target prices are widely dispersed.
*   **Hybrid signal is "buy"**
*   **Accumulative investment is recommended(MRI)**

**Recommendation:**

Due to positive Hybrid Signal, and accumulative investment suggestion based on MRI, I recommend accumulative investment.
